Skip to content

Abnormal Adiponectin Level C4073126

Published: July 22, 2026Updated: August 25, 2026

Abnormal levels of adiponectin, a hormone produced by fat cells that helps regulate metabolism. It may be linked to conditions like diabetes or obesity. Management typically involves treating underlying conditions and lifestyle changes.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
E34.9
ICD-11
5A00.0
Body system
endocrine
Severity
mild
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Shortness of breath

Difficulty breathing or feeling winded with minimal exertion, which may indicate cardiovascular complications.

Seek immediate medical attention if shortness of breath is severe or occurs at rest, as it may indicate a serious cardiovascular condition.

!

Chest discomfort

Pressure, tightness, or pain in the chest area that may occur with activity or at rest.

Seek emergency medical care immediately if chest pain is severe, crushing, or accompanied by shortness of breath, sweating, or radiating pain to the arm or jaw.

Persistent fatigue

(constitutional)

Persistent feeling of tiredness and low energy that doesn't improve with rest, often related to metabolic dysfunction.

Frequency: 70-80% of patients

Unexplained weight gain

(constitutional)

Increased body weight, particularly around the abdomen, that occurs without significant changes in diet or activity level.

Frequency: 75-85% of patients

Increased appetite

(gastrointestinal)

Persistent feelings of hunger and difficulty feeling full, often related to leptin resistance and metabolic dysregulation.

Frequency: 65-75% of patients

Elevated blood pressure

(cardiovascular)

Higher than normal blood pressure readings, often related to insulin resistance and metabolic syndrome.

Frequency: 50-60% of patients

Acanthosis nigricans

(dermatologic)

Dark, thickened patches of skin, typically appearing on the neck, armpits, or groin, indicating insulin resistance.

Frequency: 40-50% of patients

Difficulty losing weight

(constitutional)

Persistent difficulty losing weight despite diet and exercise efforts, related to metabolic and hormonal imbalances.

Frequency: 60-70% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Endocrine management

Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.

lifestyle
2

Mediterranean Diet Intervention

Adoption of a Mediterranean-style dietary pattern rich in olive oil, fruits, vegetables, whole grains, and lean proteins has been shown to improve adiponectin levels and metabolic health markers.

dietary
3

Regular Physical Exercise Program

Consistent aerobic exercise training has been demonstrated to increase adiponectin secretion and improve insulin sensitivity. A combination of moderate-intensity continuous training and interval training is recommended.

lifestyle

Additional treatment options

Weight Management Through Caloric Restriction

Modest weight reduction of 5-10% of body weight can significantly improve adiponectin levels and reduce associated metabolic risks. Focus on sustainable lifestyle changes rather than rapid weight loss.

lifestyle

Thiazolidinedione Therapy

Thiazolidinedione medications act as PPAR-gamma agonists and can increase adiponectin expression. These are typically reserved for patients with metabolic syndrome or type 2 diabetes when lifestyle measures are insufficient.

medication

Metabolic Parameter Tracking

Regular monitoring of metabolic markers including lipid profile, fasting glucose, HbA1c, and inflammatory markers alongside adiponectin levels helps assess treatment response and cardiovascular risk.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal Adiponectin Level C4073126?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.

review2006View source →
2

Katsi V, Oikonomou D, Vamvakou G, et al. Adiponectin and cardiovascular disease: A biomarker and therapeutic target. Hellenic J Cardiol. 2021;62(5):352-358.

meta_analysis2021View source →
3

Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321.

review2017View source →
4

American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20-S42.

guideline2024View source →
5

Gao H, Fall T, van der Harst P, et al. Association of adiponectin with cardiovascular disease and mortality: The Swedish Malmo Diet and Cancer Study. Eur Heart J. 2009;30(7):805-814.

clinical_trial2009View source →
6

Finucane FM, Luan J, Wareham NJ, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345-2349.

review2009View source →
7

Soedling H, Ekelund U, Wareham NJ, Langenberg C. Adiponectin and incident type 2 diabetes: An epidemiological study within the EPIC-InterAct. Cardiovasc Diabetol. 2015;14:13.

meta_analysis2015View source →
8

Endocrine Society. Endocrine Society Clinical Practice Guideline on the identification and management of metabolic dysfunction in obesity. J Clin Endocrinol Metab. 2024;109(1):1-30.

position_statement2024View source →
9

Liu M, Liu F. Regulation of adiponectin multimerization, signaling and function. Best Pract Res Clin Endocrinol Metab. 2014;28(1):25-31.

review2014View source →
10

International Diabetes Federation. IDF Consensus Worldwide Definition of Metabolic Syndrome. Brussels: International Diabetes Federation; 2006.

consensus2006View source →

Medication Comparisons

Compare medications used to treat Abnormal Adiponectin Level C4073126. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy